menu

News . Events

09.11.2017 by ChemBioSys

ChemBioSys Lectures: Andreas Marzinzik

Dr. Andreas Marzinzik

Novartis S.A., Basel, CH

 

Toward the goal of curing CML: Discovery of ABL001,

a novel allosteric inhibitor of BCR-ABL

 

 

December 4th, 18:15,  IAAC Lecture Hall Humboldt Str. 8

 

 

 

Go back